Science News
from research organizations

Sorafenib Shows Potential For Treating Some Forms Of Leukemia

Date:
January 29, 2008
Source:
Journal of the National Cancer Institute
Summary:
The drug sorafenib, which is used to treat kidney and liver cancer, may be effective acute myeloid leukemia patients with specific gene mutations. Previous studies have shown that sorafenib is especially effective against acute myeloid leukemia cells that have certain mutations known as internal tandem duplication (ITD) mutations of the Fms-like tyrosine kinase 3 (FLT3) gene.
Share:
       
FULL STORY

The drug sorafenib, which is used to treat kidney and liver cancer, may be effective acute myeloid leukemia patients with specific gene mutations.

Previous studies have shown that sorafenib is especially effective against acute myeloid leukemia cells that have certain mutations known as internal tandem duplication (ITD) mutations of the Fms-like tyrosine kinase 3 (FLT3) gene.

Michael Andreeff, M.D., Ph.D., of the University of Texas M. D. Anderson Cancer Center in Houston and colleagues examined sorafenib's ability to kill leukemia cells that express either the common form or mutant copies of FLT3. They also gave sorafenib to mice bearing leukemia cells with known FLT3 gene mutations and to leukemia patients with and without the mutations.

The researchers found that sorafenib slowed growth and induced cell death in the FLT3 mutant leukemia cells and increased survival of the mice with FLT3 mutant leukemia. Sorafenib reduced the percentage of leukemia cells in blood and marrow in patients with this mutation, but not in patients without the mutation.

"Our findings imply that sorafenib is a potent antileukemic agent in patients with FLT3-ITD mutant [acute myeloid leukemia], a form of [the disease] that responds poorly to traditional chemotherapy," the authors write.

This research was recently published in the Journal of the National Cancer Institute.


Story Source:

The above post is reprinted from materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Sorafenib Shows Potential For Treating Some Forms Of Leukemia." ScienceDaily. ScienceDaily, 29 January 2008. <www.sciencedaily.com/releases/2008/01/080129160827.htm>.
Journal of the National Cancer Institute. (2008, January 29). Sorafenib Shows Potential For Treating Some Forms Of Leukemia. ScienceDaily. Retrieved August 28, 2015 from www.sciencedaily.com/releases/2008/01/080129160827.htm
Journal of the National Cancer Institute. "Sorafenib Shows Potential For Treating Some Forms Of Leukemia." ScienceDaily. www.sciencedaily.com/releases/2008/01/080129160827.htm (accessed August 28, 2015).

Share This Page: